|
There are a multitude of medical devices that are polymer based and therefore potential candidates to be embedded with NO to render them antimicrobial. In assessing the market Enox reviewed potential devices taking into consideration market sizes and the potential paths to market.
Internal Development
Internally, the company is focused on the development of NO embedded devices within what we consider to be the most attractive markets based on size and perceived regulatory pathway. The initial target devices are endotracheal tubes and urinary catheters.
Endotracheal Tubes (ETT)
Endotracheal tubes are the principal means by which anesthesia and oxygen are administered to patients during intubation. There are approximately 20 million endotracheal tubes sold within the US and 30 million in the rest of the world1 . Market annual growth is estimated to be 5.5%2.
|
Urinary Catheter
A urinary catheter is any tube system placed in the body to drain urine from the bladder. Foley catheters, are an optimal candidates for NO dosing and are anchored in the bladder with an inflatable balloon.3. In the United States there are 25 million Foley catheters sold annually and there are 75 million catheters sold elsewhere yielding a total global Foley catheter market of 100 million units worldwide. 4 |
1 Frost and Sullivan 2003 Domike KR. 2004.
2 The Impact of improved Metirial in Poly-Based Endotracheal Tubes.
3 Newman, J Wound Ostomy Continence Nurs 2007; 34:655-661
4 Arch Intern Med. 2000 Sep 25;160(17):2670-5 |
|
Licensing Partnerships
Concurrent with the internal development of endotracheal tubes and urinary catheters, the Enox will seek strategic partners to license its NO technology at a pre-clinical stage for additional applications. With the NO technology potentially combined with a wide range of medical devices, there are many potential applications which include but are not limited to tympanostomy tubes, cosmetic implants, penile prostheses, dialysis catheter, central venous catheters, device connectors, drainage tubes, and temporary intra-vaginal implants for the treatment of yeast and bacterial infections.
In December 2010 Enox entered into a licensing partnership with Ortho Dental Solutions LTD granting them the rights to patent application and knowhow for use in developing novel therapies limited in use for dental and gum diseases. Periodontal disease is one of the most common diseases throughout the world which, if left untreated, can lead to tooth loss. It is a chronic bacterial infection that affects the gums and bone supporting the teeth. Periodontal disease is associated with biofilm and its formation that causes the gums to become inflamed and infected. Ortoh Dental Solutions will develop products using the Enox formulation to provide solutions for conservative treatment and control of periodontal disease. |
